Topiramate add-on treatment associated with normalization of prolactin levels in a patient with schizophrenia.

about

Topiramate add-on treatment associated with normalization of prolactin levels in a patient with schizophrenia.

Item

http://www.wikidata.org/entity/Q42058133

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Topiramate add-on treatment as ...... a patient with schizophrenia.

@en

Topiramate add-on treatment as ...... a patient with schizophrenia.

@nl

type

Item

label

Topiramate add-on treatment as ...... a patient with schizophrenia.

@en

Topiramate add-on treatment as ...... a patient with schizophrenia.

@nl

prefLabel

Topiramate add-on treatment as ...... a patient with schizophrenia.

@en

Topiramate add-on treatment as ...... a patient with schizophrenia.

@nl

P1476

Topiramate add-on treatment as ...... n a patient with schizophrenia

@en

P2093

Gang Zhu

http://www.w3.org/2001/XMLSchema#string

Huan Ma

http://www.w3.org/2001/XMLSchema#string

Miao Peng

http://www.w3.org/2001/XMLSchema#string

Yuan Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Review of the use of Topiramate for treatment of psychiatric disorders

Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.

Prolactin and dopamine: what is the connection? A review article.

Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.

Biphasic actions of topiramate on monoamine exocytosis associated with both soluble N-ethylmaleimide-sensitive factor attachment protein receptors and Ca(2+)-induced Ca(2+)-releasing systems.

Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial.

Topiramate augments the antipsychotic-like effect and cortical dopamine output of raclopride.

Prolactin-derived vasoinhibins increase anxiety- and depression-related behaviors.

P304

1395-1397

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.2147/NDT.S135666

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yinglin Huang

P577

2017-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28579786

http://www.w3.org/2001/XMLSchema#string

P921

schizophrenia

P932

5449160

http://www.w3.org/2001/XMLSchema#string